The atypical PKC-interacting protein p62 is an important mediator of RANK-activated osteoclastogenesis

被引:265
作者
Durán, A
Serrano, M
Leitges, M
Flores, JM
Picard, S
Brown, JP
Moscat, J [1 ]
Diaz-Meco, MT
机构
[1] Univ Autonoma Madrid, CSIC, Ctr Nacl Biotecnol, Ctr Biol Mol Severo Ochoa, E-28049 Madrid, Spain
[2] Univ Autonoma Madrid, CSIC, Ctr Nacl Biotecnol, Dept Inmunol & Oncol, E-28049 Madrid, Spain
[3] Max Planck Inst Expt Endokrinol, D-30625 Hannover, Germany
[4] Univ Complutense, Fac Vet, Dept Med & Cirugia Anim, E-28040 Madrid, Spain
[5] Univ Laval, CHUL, Ctr Rech, Grp Rech Malad Osseuses, Ste Foy, PQ G1V 4G2, Canada
关键词
D O I
10.1016/S1534-5807(03)00403-9
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
The atypical PKCs (aPKCs) have been implicated genetically in at least two independent signaling cascades that control NF-kappaB and cell polarity, through the interaction with the adapters p62 and Par-6, respectively. P62 binds TRAF6, which plays an essential role in osteoclastogenesis and bone remodeling. Recently, p62 mutations have been shown to be the cause of the 5q35-linked Paget's disease of bone, a genetic disorder characterized by aberrant osteoclastic activity. Here we show that p62, like TRAF6, is upregulated during RANK-L-induced osteoclastogenesis and that the genetic inactivation of p62 in mice leads to impaired osteoclastogenesis in vitro and in vivo, as well as inhibition of IKK activation and NF-kappaB nucleartranslocation. In addition, RANK-L stimulation leads to the inducible formation of a ternary complex involving TRAF6, p62, and the aPKCs. These observations demonstrate that p62 is an important mediator during osteoclastogenesis and induced bone remodeling.
引用
收藏
页码:303 / 309
页数:7
相关论文
共 28 条
[1]   TARF6 is a signal transducer for interleukin-1 [J].
Cao, ZD ;
Xiong, J ;
Takeuchi, M ;
Kurama, T ;
Goeddel, DV .
NATURE, 1996, 383 (6599) :443-446
[2]   A DOMINANT-NEGATIVE PROTEIN-KINASE-C ZETA-SUBSPECIES BLOCKS NF-KAPPA-B ACTIVATION [J].
DIAZMECO, MT ;
BERRA, E ;
MUNICIO, MM ;
SANZ, L ;
LOZANO, J ;
DOMINGUEZ, I ;
DIAZGOLPE, V ;
DELERA, MTL ;
ALCAMI, J ;
PAYA, CV ;
ARENZANASEISDEDOS, F ;
VIRELIZIER, JL ;
MOSCAT, J .
MOLECULAR AND CELLULAR BIOLOGY, 1993, 13 (08) :4770-4775
[3]   Essential role of RelA Ser311 phosphorylation by ζPKC in NF-κB transcriptional activation [J].
Duran, A ;
Diaz-Meco, MT ;
Moscat, J .
EMBO JOURNAL, 2003, 22 (15) :3910-3918
[4]   Requirement for NF-κB in osteoclast and B-cell development [J].
Franzoso, G ;
Carlson, L ;
Xing, LP ;
Poljak, L ;
Shores, EW ;
Brown, KD ;
Leonardi, A ;
Tran, T ;
Boyce, BF ;
Siebenlist, U .
GENES & DEVELOPMENT, 1997, 11 (24) :3482-3496
[5]   Missing pieces in the NF-κB puzzle [J].
Ghosh, S ;
Karin, M .
CELL, 2002, 109 :S81-S96
[6]   Domain-specific mutations in sequestosome 1 (SQSTM1) cause familial and sporadic Paget's disease [J].
Hocking, LJ ;
Lucas, GJA ;
Daroszewska, A ;
Mangion, J ;
Olavesen, M ;
Cundy, T ;
Nicholson, GC ;
Ward, L ;
Bennett, ST ;
Wuyts, W ;
Van Hul, W ;
Ralston, SH .
HUMAN MOLECULAR GENETICS, 2002, 11 (22) :2735-2739
[7]   Osteopetrosis in mice lacking NF-kappa B1 and NF-kappa B2 [J].
Iotsova, V ;
Caamano, J ;
Loy, J ;
Yang, Y ;
Lewin, A ;
Bravo, R .
NATURE MEDICINE, 1997, 3 (11) :1285-1289
[8]   Segregation of TRAF6-mediated signaling pathways clarifies its role in osteoclastogenesis [J].
Kobayashi, N ;
Kadono, Y ;
Naito, A ;
Matsumoto, K ;
Yamamoto, T ;
Tanaka, S ;
Inoue, J .
EMBO JOURNAL, 2001, 20 (06) :1271-1280
[9]   TRAF6 is a critical factor for dendritic cell maturation and development [J].
Kobayashi, T ;
Walsh, PT ;
Walsh, MC ;
Speirs, KM ;
Chiffoleau, E ;
King, CG ;
Hancock, WW ;
Caamano, JH ;
Hunter, CA ;
Scott, P ;
Turka, LA ;
Choi, YW .
IMMUNITY, 2003, 19 (03) :353-363
[10]  
Lallena MJ, 1999, MOL CELL BIOL, V19, P2180